Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSTOP-CP intranasal MSCs for perinatal hypoxic-ischemic brain injury
2025-521506-17-01Phase 2Authorised
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2026
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of Provacel in hypoxic-ischemic encephalopathy (HIE), asphyxia neonatorum, perinatal arterial ischemic stroke (PAIS) and 1 more, sponsored by University Medical Center Utrecht. Primary endpoint: Bayley-IV-NL motor score at 24 months. Planned start Jul 2026; status: authorised.
02
Drugs
Provacel
03
Conditions
hypoxic-ischemic encephalopathy (HIE)asphyxia neonatorumperinatal arterial ischemic stroke (PAIS)cerebral palsy (CP)
Beyond the preview
Go deeper on 2025-521506-17-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521506-17-01.